GlassScriptPhysician profile
Danica Schulte
NPI 1386645083
$7,547.43
in general payments reported to CMS, 2019-2025
28 companies · $3,218 in 2025
The $3,218 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $284 · 2021: $348 · 2022: $1,672 · 2023: $676 · 2024: $1,013 · 2025: $3,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Education: $17.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Education | $17.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,988.69 | 2019-2025 | Dupixent |
| Kaleo, INC. | $1,241.36 | 2020-2025 | Auvi-Q |
| Csl Behring | $538.79 | 2019-2025 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $438.17 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $435.49 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $379.90 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $345.88 | 2024-2025 | Orladeyo |
| Pfizer INC. | $338.17 | 2019-2024 | |
| Genzyme Corporation | $316.32 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $270.56 | 2020-2024 | Cuvitru, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $163.02 | 2025 | Neffy |
| Genentech USA, INC. | $151.70 | 2019-2025 | Xolair |
| Amgen INC. | $150.12 | 2022-2025 | Tezspire |
| Incyte Corporation | $92.29 | 2021-2025 | Opzelura |
| Aimmune Therapeutics, INC. | $84.63 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $83.16 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $82.67 | 2020-2021 | |
| Alk-Abello, INC | $67.45 | 2020-2023 | Odactra, Grastek, Ragwitek |
| Shire North American Group INC | $61.64 | 2019 | |
| Greer Laboratories, INC. | $57.34 | 2025 | Oralair |
| Octapharma USA, INC. | $48.49 | 2023-2024 | Cutaquig |
| Hikma Pharmaceuticals USA | $41.93 | 2023 | Ryaltris |
| Phadia US INC. | $36.70 | 2022-2025 | Immunocap |
| Grifols USA, LLC | $30.71 | 2024 | Prolastin-C Liquid |
| Bio Products Laboratory USA, INC. | $29.82 | 2023 | Gammaplex, Coagadex |
| Leo Pharma INC. | $26.73 | 2022 | |
| Horizon Therapeutics Plc | $23.09 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.61 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danica Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.